Table 2 Demographic and clinical characteristics of patients with Intrahepatic cholangiocarcinoma in the CSS group. IQR interquartile range.

Total patients, n

1387

970

417

Age, n (%)

0.816

 < 50

170 (12.3%)

122 (12.6%)

48 (11.5%)

 50–64

527 (38.0%)

361 (37.2%)

166 (39.8%)

 65–79

593 (42.8%)

418 (43.1%)

175 (42.0%)

 ≥ 80

97 (7.0%)

69 (7.1%)

28 (6.7%)

Sex, n (%)

0.876

 Male

714 (51.5%)

498 (51.3%)

216 (51.8%)

 Female

673 (48.5%)

472 (48.7%)

201 (48.2%)

Race, n (%)

0.383

 White

1081 (77.9%)

749 (77.2%)

332 (79.6%)

 Black

116 (8.4%)

80 (8.2%)

36 (8.6%)

 Other

190 (13.7%)

141 (14.5%)

49 (11.8%)

AJCC T stage, n (%)

0.227

 T1

422 (30.4%)

304 (31.3%)

118 (28.3%)

 T2

643 (46.4%)

433 (44.6%)

210 (50.4%)

 T3

216 (15.6%)

159 (16.4%)

57 (13.7%)

 T4

106 (7.6%)

74 (7.6%)

32 (7.7%)

AJCC N stage, n (%)

0.315

 N0

921 (66.4%)

636 (65.6%)

285 (68.3%)

 N1

466 (33.6%)

334 (34.4%)

132 (31.7%)

AJCC M stage, n (%)

0.777

 M0

1048 (75.6%)

735 (75.8%)

313 (75.1%)

 M1

339 (24.4%)

235 (24.2%)

104 (24.9%)

Grade, n (%)

0.350

 I

139 (10.0%)

98 (10.1%)

41 (9.8%)

 II

655 (47.2%)

446 (46.0%)

209 (50.1%)

 III + IV

593 (42.8%)

426 (43.9%)

167 (40.0%)

Tumor size, n (%)

0.261

 ≤ 5 cm

476 (34.3%)

342 (35.3%)

134 (32.1%)

 > 5 cm

911 (65.7%)

628 (64.7%)

283 (67.9%)

Surgery, n (%)

0.200

 No

722 (52.1%)

494 (50.9%)

228 (54.7%)

 Yes

665 (47.9%)

476 (49.1%)

189 (45.3%)

Chemotherapy, n (%)

0.014

 No

520 (37.5%)

384 (39.6%)

136 (32.6%)

 Yes

867 (62.5%)

586 (60.4%)

281 (67.4%)

Radiotherapy, n (%)

0.242

 No

1163 (83.9%)

806 (83.1%)

357 (85.6%)

 Yes

224 (16.1%)

164 (16.9%)

60 (14.4%)

Survival, median (IQR)

15 (7.0, 28.00)

15 (6.0, 29.00)

16 (7.0, 27.00)